Pembrolizumab Monotherapy Effective for Rare Melanoma
Pembrolizumab led to a dramatic overall response rate among patients with unresectable desmoplastic melanoma.
United States Bristol Myers Squibb Kari Kendra Zeynep Aroglu Ohio State University Wexner Medical Center Boehringer Ingelheim
Source: medscape.com